Trials / Completed
CompletedNCT04702958
TRANSFORM-HF Ancillary Mechanistic Study
Mechanistic Insights From Longitudinal Changes in Blood and Urine Proteins to Explain Efficacy and Safety of Torsemide vs Furosemide After a Heart Failure Hospitalization
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Inova Health Care Services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.
Detailed description
Patients who are enrolling in the TRANSFORM-HF study or being prescribed Torsemide or Furosemide at hospital discharge will provide blood and urine at the time of study enrollment (within 72 hours of hospital discharge) and at 90 days (+/- one week) after hospital discharge.
Conditions
Timeline
- Start date
- 2020-12-10
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
- First posted
- 2021-01-11
- Last updated
- 2023-10-10
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04702958. Inclusion in this directory is not an endorsement.